ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 28664385

Pazopanib: a Review in Advanced Renal Cell Carcinoma.

Frampton JE. Target Oncol, 2017. Cited by 26 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pazopanib: a Review in Advanced Renal Cell Carcinoma. Papers, record 28664385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28664385

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pazopanib: a Review in Advanced Renal Cell Carcinoma.
PubMed
Journal
Target Oncol
PubMed
Year
2017
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
0.87
iCite
Revised in PubMed
2021-12-04
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Frampton JEJames E

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angiogenesis InhibitorsMajor topic
Carcinoma, Renal CellMajor topic
PyrimidinesMajor topic
SulfonamidesMajor topic
Female
Humans
Indazoles
Male

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117,620,431Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.Mol Cancer Ther2007https://conductscience.org/library/papers/17620431PubMed
227,000,445Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.Cancer2016https://conductscience.org/library/papers/27000445PubMed
326,088,013Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib.Oncology2015https://conductscience.org/library/papers/26088013PubMed
424,785,224Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.N Engl J Med2014https://conductscience.org/library/papers/24785224PubMed
524,107,802Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.Ann Oncol2013https://conductscience.org/library/papers/24107802PubMed
626,546,620HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.Clin Cancer Res2016https://conductscience.org/library/papers/26546620PubMed
726,011,553Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.J Manag Care Spec Pharm2015https://conductscience.org/library/papers/26011553PubMed
824,687,826Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.J Clin Oncol2014https://conductscience.org/library/papers/24687826PubMed
927,568,124Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.Clin Genitourin Cancer2017https://conductscience.org/library/papers/27568124PubMed
1027,490,806Medical treatment of renal cancer: new horizons.Br J Cancer2016https://conductscience.org/library/papers/27490806PubMed

1 to 10 of 45

See all 45 references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
42,780,318A case of recurrent acute acalculous cholecystitis in a patient with renal cell carcinoma treated with pazopanib and axitinib: case report and literature review.Front Pharmacol2026https://conductscience.org/library/papers/42780318PubMed
41,646,210Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.ESMO Real World Data Digit Oncol2025https://conductscience.org/library/papers/41646210PubMed
41,268,304Neoadjuvant tislelizumab plus pazopanib in renal cell carcinoma with venous tumour thrombus: A retrospective study.BJUI Compass2025https://conductscience.org/library/papers/41268304PubMed
41,211,418Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer.Front Oncol2025https://conductscience.org/library/papers/41211418PubMed
40,240,354Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma.Cell Death Dis2025https://conductscience.org/library/papers/40240354PubMed
39,936,438Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects.Curr Top Med Chem2025https://conductscience.org/library/papers/39936438PubMed
39,161,771Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance.Front Immunol2024https://conductscience.org/library/papers/39161771PubMed
39,000,399Long-Term Remission with Novel Combined Immune-Targeted Treatment for Histiocytic Sarcoma Accompanied by Follicular Lymphoma: Case Report and Literature Review.Int J Mol Sci2024https://conductscience.org/library/papers/39000399PubMed
37,649,689Renal cell carcinoma not otherwise specified: A case report in Indonesia.Urol Case Rep2023https://conductscience.org/library/papers/37649689PubMed
37,384,288Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.Front Oncol2023https://conductscience.org/library/papers/37384288PubMed

1 to 10 of 21

See all 21 cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FLT12,321PubTator's text mininghttps://conductscience.org/library/genes/2321NCBI Gene
FLT42,324PubTator's text mininghttps://conductscience.org/library/genes/2324NCBI Gene
KDR3,791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KIT3,815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
PDGFRA5,156PubTator's text mininghttps://conductscience.org/library/genes/5156NCBI Gene
PDGFRB5,159PubTator's text mininghttps://conductscience.org/library/genes/5159NCBI Gene
TXK7,294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28664385

GET https://conductscience.org/api/papers/v1/28664385/references?page=2

API referenceFor AI assistants